In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET.
UNLABELLED
PET radioligand binding to the 18-kD translocator protein (TSPO) in the brains of patients with multiple sclerosis (MS) primarily reflects activated microglia and macrophages. We previously developed genetic stratification for accurate quantitative estimation of TSPO using second-generation PET radioligands. In this study, we used (18)F-PBR111 PET and MR imaging to measure relative binding in the lesional, perilesional, and surrounding normal-appearing white matter of MS patients, as an index of the innate immune response.


METHODS
(18)F-PBR111 binding was quantified in 11 MS patients and 11 age-matched healthy volunteers, stratified according to the rs6971 TSPO gene polymorphism. Fluid-attenuated inversion recovery and magnetization transfer ratio (MTR) MR imaging were used to segment the white matter in MS patients as lesions, perilesional volumes, nonlesional white matter with reduced MTR, and nonlesional white matter with normal MTR.


RESULTS
(18)F-PBR111 binding was higher in the white matter lesions and perilesional volumes of MS patients than in white matter of healthy controls (P < 0.05). Although there was substantial heterogeneity in binding between different lesions, a within-subject analysis showed higher (18)F-PBR111 binding in MS lesions (P < 0.05) and in perilesional (P < 0.05) and nonlesional white matter with reduced MTR (P < 0.005) than in nonlesional white matter with a normal MTR. A positive correlation was observed between the mean (18)F-PBR111 volume of distribution increase in lesions relative to nonlesional white matter with a normal MTR and the MS severity score (Spearman ρ = 0.62, P < 0.05).


CONCLUSION
This study demonstrates that quantitative TSPO PET with a second-generation radioligand can be used to characterize innate immune responses in MS in vivo and provides further evidence supporting an association between the white matter TSPO PET signal in lesions and disease severity. Our approach is practical for extension to studies of the role of the innate immune response in MS for differentiation of antiinflammatory effects of new medicines and their longer term impact on clinical outcome.
['Colasanti|Alessandro|A|', 'Guo|Qi|Q|', 'Muhlert|Nils|N|', 'Giannetti|Paolo|P|', 'Onega|Mayca|M|', 'Newbould|Rexford D|RD|', 'Ciccarelli|Olga|O|', 'Rison|Stuart|S|', 'Thomas|Charlotte|C|', 'Nicholas|Richard|R|', 'Muraro|Paolo A|PA|', 'Malik|Omar|O|', 'Owen|David R|DR|', 'Piccini|Paola|P|', 'Gunn|Roger N|RN|', 'Rabiner|Eugenii A|EA|', 'Matthews|Paul M|PM|']
D000328:Adult D000368:Aged D016022:Case-Control Studies D005260:Female D006801:Humans D007249:Inflammation D008264:Macrophages D008297:Male D017628:Microglia D008875:Middle Aged D009103:Multiple Sclerosis D049268:Positron-Emission Tomography D011725:Pyridines D015203:Reproducibility of Results D066127:White Matter
multiple sclerosis PET TSPO microglia lesion MTR